Securing a New Momentum in the Psychedelic-Based Therapeutics Market

Jupiter Neurosciences has entered the psychedelic-based mental health therapeutics market by entering into an exclusive license agreement with PharmAla Biotech, a Canadian company, for 'ALA-002,' a patented non-racemic 3,4-methylenedioxymethamphetamine (MDMA) formulation, granting Jupiter exclusive rights in the U.S. ALA-002 has been designated as a Novel Chemical Entity (NCE) by the U.S. Food and Drug Administration (FDA), which will allow it to secure strong regulatory barriers and data exclusivity upon commercialization. This deal represents a significant turning point for Jupiter, allowing it to diversify its business portfolio from its existing Parkinson's disease and Alzheimer's disease-targeting resveratrol pipeline, JOTROL, into the clinical-stage central nervous system (CNS) area. Through this, Jupiter has quickly positioned itself as a leading player in the high-value psychedelic therapeutics market.

A Strategic $100 Million Deal Structure with Minimized Risk

The total value of this transaction is up to $100 million (USD$100,000,000), but the initial upfront payment is set at $3.33 million, consisting of $1.5 million in cash and $1.83 million in Jupiter common stock, significantly reducing the initial capital outflow burden. The remaining $96.67 million will be paid in stages, including $3.33 million upon the first patient being dosed in the Phase 3 clinical trial in the U.S., and $20 million upon FDA approval of the New Drug Application (NDA), establishing a risk-sharing structure that is closely linked to clinical and regulatory milestones. In addition, PharmAla will retain exclusive rights to global regions outside the U.S. and will separately pursue a contract manufacturing and supply agreement to supply Jupiter with drugs that meet Good Manufacturing Practice (GMP) standards, thereby reducing development risk and maximizing mutual milestone revenues and supply chain stability, creating a win-win structure.

Targeting a Niche Market Created by Lykos' Regulatory Failure

Recently, Lykos Therapeutics, a leading company in the psychedelic market, received a Complete Response Letter (CRL) from the FDA in August 2024 for its racemic MDMA therapy due to serious cardiovascular side effects, abuse potential, and inadequate control in the clinical design, leading to extreme uncertainty in the market. However, ALA-002, developed by PharmAla, is designed to maintain the therapeutic efficacy of existing MDMA while selectively controlling receptor activity that causes cardiovascular toxicity and reducing drug dependence, making it a promising alternative to overcome the FDA's stricter clinical standards. Therefore, this agreement is evaluated as a sophisticated strategy to circumvent and seize the U.S. market by taking advantage of the regulatory hurdles faced by its competitors and focusing on a safer, next-generation therapy.

Aiming to Secure a Multi-Billion Dollar PTSD Market

The global post-traumatic stress disorder (PTSD) treatment market is currently valued at approximately $2 billion to $2.4 billion, primarily in the U.S., but there is a high unmet medical need in this area due to the low response rates and high relapse rates of existing selective serotonin reuptake inhibitor (SSRI) drugs. By securing exclusive rights to develop and commercialize ALA-002 in the U.S., Jupiter will be able to secure a strong commercial foothold and exclusive position, with the potential to generate hundreds of millions of dollars in annual revenue upon regulatory approval. The bio-investment industry expects that the timing of entry into Phase 3 clinical trials in the U.S. and the compliance with clinical protocols and control of toxicity data in the initial patient dosing phase will be key factors in determining Jupiter's stock price and corporate value.